History eliciting symptoms and physical examination every 3-6 months for 3 years , then 6-12 months for 3 years, then annually with attention paid to long term side-effects (osteoporosis).

Ipsilateral and contralateral radiology every year.

Not routinely recommended for asymptomatic patients: blood counts; chemistry, chest Xray, bone scan, liver ultrasound, chest scans of chest or abdomen and any tumour marker such as CA 153, CEA are not recommended.

Serum tumour markers should be used only as a guide to aid treatment decisions and monitor response of not easily measurable disease in the metastatic breast cancer settings and not for screening or diagnosis.

The proliferation marker Ki-67 provides important prognostic, particularly for patients with small tumours and no axillary node involvement.

Oestrogen and progesterone receptors and their degree of positive are excellent predictors of response in all patients with breast cancer and aid the multi-disciplinary team as to which hormonal therapy should be used.